Merck Wins Fosamax Side Effects Trial

Atlantic City, NJDrugmaker Merck & Co. won the latest jury trial involving Fosamax side effects regarding a Pennsylvania woman who claimed the osteoporosis drug caused her jaw to deteriorate, according to the Dow Jones Newswires. 

span itemprop="image" itemscope itemtype="https://schema.org/ImageObject" style="display:block">The news source reports that a state court jury in Atlantic City, New Jersey, rejected the claims made by Alison Rosenberg that the medication had caused her to develop osteonecrosis and that the company did not properly warn of the drug's risks.

An attorney for Rosenberg said that his client was "deeply disappointed" with the jury verdict, adding that an appeal is planned because the drug company "can't keep getting away with hiding the risks of their drugs."

According to the news provider, Merck is facing approximately 1,180 Fosamax cases, the majority of which are associated with osteonecrosis. The verdict marks the third trial victory for the drugmaker in Fosamax cases.

Osteonecrosis is most common in people between the ages of 30 and 60, according to the National Center for Biotechnology Information.